Drug Profile
Research programme: antibacterials - Inflazyme
Alternative Names: Antibacterials research programme - Inflazyme; APT 3088; Prodaptin vancomycinLatest Information Update: 02 Aug 2005
Price :
$50
*
At a glance
- Originator Inflazyme Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 30 Apr 2005 Discontinued - Preclinical for Bacterial infections in United Kingdom (unspecified route)
- 21 Apr 2004 Adprotech has been acquired by Inflazyme Pharmaceuticals
- 11 Nov 2002 Preclinical trials in Bacterial infections in United Kingdom (unspecified route)